Escitalopram reduces anger and irritability in premenstrual dysphoric disorder, study finds

A recent study conducted in Sweden has found that escitalopram, a selective serotonin reuptake inhibitor (SSRI), is effective in reducing irritability and anger in women with premenstrual dysphoric disorder (PMDD). The research focused on the impact of the medication during the luteal phase of the menstrual cycle, which is the time before menstruation.

PMDD is a severe form of premenstrual symptoms that can significantly interfere with daily life, work, relationships, and overall well-being. The study involved 62 women with PMDD, aged 34 on average, who were randomly assigned to either receive escitalopram (20 mg per day) or a placebo for up to 15 days in the luteal phase. The primary outcome was the reduction in PMDD symptoms, while secondary outcomes included specific mood and anger-related symptoms.

The results showed that participants who received escitalopram had lower overall PMDD symptom scores, as well as lower depression, affective lability, irritability, and anger scores compared to the placebo group. The decrease in irritability and anger was particularly notable. Additionally, functional magnetic resonance imaging (fMRI) revealed that escitalopram treatment led to reduced neural reactivity to aggression-related stimuli in the anterior insula, a brain region involved in threat detection and associated with irritability and anger.

These findings suggest that escitalopram is an effective treatment for PMDD, particularly in reducing irritability and anger, and that its effects may be mediated by changes in serotonin function within corticolimbic circuits.